Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

PolyU discovers the effect of chemical compound PTU on autophagy in zebrafish embryos, sheds light on cancer medication research
  • USA - English

The zebrafish has been utilised as a model organism for biomedical research globally for half a century, mainly due to the high genetic similarity (over 70%) between zebrafish and human genes, with over 80% of human morbid genes related to at least one zebrafish orthologue. As test subjects, zebrafish are suitable for high throughput applications (to screen a large amount of genetic data simultaneously) and are widely used as a model organism for studying vertebrate development and for characterising diseases such as cancer, to help in identifying and testing new drugs. Fast development, cost-effective and easy to breed are also primary drivers for using the zebrafish research model. However, a recent research project led by Dr Alvin MA Chun-hang, Assistant Professor of the Department of Health Technology and Informatics, The Hong Kong Polytechnic University (PolyU), has revealed that the conventional application of 1-phenyl 2-thiourea (PTU), a pigment suppresser used in the zebrafish research model, may affect the results of autophagy-related studies. This ground-breaking finding subsequently sheds light on the respective research guidelines and the research protocol in on-going studies on autophagy and haematology, warranting researchers to re-examine research that is linked to existing cancer therapy options. The research titled "1-phenyl 2-thiourea (PTU) Activates Autophagy in Zebrafish Embryos" was published in Autophagy, a peer-reviewed science journal in April 2020.


News provided by

The Hong Kong Polytechnic University

Jul 09, 2020, 10:00 ET

Share this article

Share toX

Share this article

Share toX

Professor YIP Shea-ping (right), Head of PolyU’s Department of HTI said that this ground-breaking discovery will be included in the new guidelines on autophagy research this year.
Professor YIP Shea-ping (right), Head of PolyU’s Department of HTI said that this ground-breaking discovery will be included in the new guidelines on autophagy research this year.

HONG KONG, July 9, 2020 /PRNewswire-PRWeb/ -- In most research using the zebrafish model, a chemical compound called 1-phenyl-2-thiourea (PTU) is commonly used to suppress pigment formation in zebrafish embryos, maintaining optical transparency to facilitate microscopic imaging. Over the past three years, the PolyU research team led by Dr MA has been using the zebrafish model to investigate the causes of leukaemia and its relationship with autophagy (self-eating) – a mechanism of metabolism that involves the degradation of cells by lysosomes and the process of cell renewal and regeneration. It is a cellular reaction to various physiological and pathological conditions regulating important processes, including intracellular material turnover, cell death, proliferation, development, ageing and tumourigenesis.

According to Dr Ma, "Upon 0.003% PTU treatment, aberrant autophagosome and autolysosome formation, accumulation of lysosomes and elevated autophagic flux were observed in various tissues and organs of the zebrafish," He pointed out that "Autophagy is crucial in the process of drug resistance of various cells and over-activation of autophagy may potentially interfere with the efficacy of drugs. The research finding means that when we are using this prominent model to study any autophagy-related processes like cancer, the results may not be truly reflected. These studies could have produced skewed results. Researchers should avoid using PTU in autophagy-related research in the future." Dr MA added that the team has already suspended the use of PTU in zebrafish research. Light-sheet microscopy, which offers greater imaging depth, will be employed as an alternative, for image autophagy in the zebrafish embryo with pigment for their study on leukaemia.

Furthermore, the new research findings also provide a direct mechanistic link between autophagy and melanoma, suggesting autophagy probably regulates melanoma development and drug resistance through interaction with tyrosinase, a key rate-limited regulator of melanin synthesis. Investigation into details of the molecular mechanism between autophagy and melanoma is expected in the future.

Professor YIP Shea-ping, Head of Department of Health Technology and Informatics, said, "We are pleased to see our research team's recent discovery published in Autophagy, the highest impact journal in the field. Dr MA has also been invited as co-author for new guidelines on autophagy research using zebrafish embryos, a revision that takes place every four years. With the new guidelines in place, we will be able to modify the way we conduct autophagy-related studies with the zebrafish model and, hopefully, to open the door to new treatments for various deadly diseases."

SOURCE The Hong Kong Polytechnic University

Related Links

https://www.polyu.edu.hk/en/

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.